PBLS (Parabilis Medicines) Short-Term Debt: $13.08 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $31.43
! 1 Warning Sign
View Full Analysis

What is Parabilis Medicines Short-Term Debt?

Parabilis Medicines PBLS -4.21% 10 Short-Term Debt is $13.08 Mil as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Parabilis Medicines's Short-Term Debt for the quarter that ended in Dec. 2025 was $13.08 Mil.

Parabilis Medicines's quarterly Short-Term Debt increased from . 20 ($0.00 Mil) to Dec. 2024 ($2.50 Mil) and increased from Dec. 2024 ($2.50 Mil) to Dec. 2025 ($13.08 Mil).

Parabilis Medicines's annual Short-Term Debt increased from . 20 ($0.00 Mil) to Dec. 2024 ($2.50 Mil) and increased from Dec. 2024 ($2.50 Mil) to Dec. 2025 ($13.08 Mil).

Parabilis Medicines Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Parabilis Medicines Short-Term Debt Related Terms

Parabilis Medicines Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines Short-Term Debt Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
Short-Term Debt
2.50 13.08

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
Short-Term Debt 2.50 13.08
PBLS
10GF Score
Parabilis Medicines Inc PBLS
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $13.08 Mil mean?
Parabilis Medicines (PBLS) has a Short-Term Debt of $13.08 Mil as of Dec. 2025.
Is Parabilis Medicines' Short-Term Debt too high?
Parabilis Medicines' current Short-Term Debt is $13.08 Mil. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Short-Term Debt compare to IDYA and ELVN?
Parabilis Medicines' Short-Term Debt of $13.08 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Parabilis Medicines's current Short-Term Debt is $13.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Short-Term Debt of $13.08 Mil. The current Short-Term Debt is $13.08 Mil. Parabilis Medicines' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Short-Term Debt is $13.08 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.43
Price